Long‐acting beta2‐agonist plus tiotropium vs long‐acting beta2‐agonist alone
Quality of life SGRQ responder analysis at 6 months · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium probably leads to higher quality of life SGRQ responder analysis at 6 months compared with long‐acting beta2‐agonist alone (moderate certainty).
1 finding from 1 review
- Long‐acting beta₂‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta₂‐agonist alone for… 2015 · Cochrane Headline outcomes onlyOR 1.53 [1.31, 1.79]2 studies · 2923 participantsModerate